Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
HK$ 18.9
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, focuses on the research and development of biologic therapies for autoimmune and allergic diseases in the People's Republic of China. The company's lead product candidates include QX002N, an interleukin (IL)-17A inhibitor in Phase III clinical trial for the treatment of ankylosing spondylitis and lupus nephritis; and QX005N,...
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E.
Data is available to registered users only
Buy
Sell